NVWM LLC’s Clovis Oncology, Inc. CLVS Stock Holding History

NVWM LLC’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-800	Closed	-$3K	–	373
2019 Q3	$3K	Buy	+800	New	+$6.47K	﹤0.01%	324

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

NVWM LLC's CLVS Position: Q4 2019 in Review

NVWM LLC sold out of Clovis Oncology, Inc. (CLVS) in Q4 2019, closing a stake of 800 shares — an estimated $3K sold.

NVWM LLC first reported a position in CLVS in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 147 funds tracked by Wall St. Rank hold CLVS as of Q4 2019.

NVWM LLC reported no remaining Clovis Oncology, Inc. position as of Q4 2019 after selling out during the quarter.
NVWM LLC sold 800 Clovis Oncology, Inc. shares in Q4 2019, an estimated $3K.
NVWM LLC first reported a position in Clovis Oncology, Inc. in Q3 2019 and held it in 1 quarter.
NVWM LLC's Clovis Oncology, Inc. position peaked at $3K in Q3 2019.
147 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2019.

Based on NVWM LLC's 13F filing for Q4 2019, filed 7 Feb 2020.